Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies

Napolitano, Mariasanta; Mancuso, Salvatrice; Coco, Lucio Lo; Arfò, Piera Stefania; Raso, Simona; Francisci, G. De; Dieli, Francesco; Caccamo, Nadia; Reina, Amalia; Dolce, Alberto; Agliastro, Rosalia; Siragusa, Sergio

doi:10.1016/j.transci.2018.07.020

Cited by 6 publications

(12 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are in line with previous in vitro data, that showed that cryopreserved platelets reduced clotting times compared to liquid stored platelets. [27][28][29] The reason why cryopreserved platelets compared to liquid stored platelets reduce ROTEM clotting times might be due to increased procoagulant microparticle content and increased thrombin generation. 16,30 We found that clot firmness was slightly reduced in the cryopreserved platelet group, although this effect was smaller than found in previous in vitro studies.…”

Section: Discussionmentioning

confidence: 99%

The use of cryopreserved platelets in a trauma‐induced hemorrhage model

et al. 2020

View full text Add to dashboard Cite

Background Cryopreserved platelet products can be stored for years and are mainly used in military settings. Following thawing, cryopreserved platelets are activated, resulting in faster clot formation but reduced aggregation in vitro, rendering their efficacy in bleeding unknown. Also, concerns remain on the safety of these products. The aim was to investigate the efficacy and safety of cryopreserved platelets in a rat model of traumatic hemorrhage. Study Design and Methods After 1 hour of shock, rats (n = 13/group) were randomized to receive a balanced transfusion pack (1:1:1 red blood cell:plasma:platelet) made from syngeneic rat blood, containing either liquid stored platelets or cryopreserved platelets. Primary outcome was the transfusion volume required to obtain a mean arterial pressure (MAP) of 60 mmHg. Secondary outcomes were coagulation as assessed by thromboelastometry (ROTEM®) and organ failure as assessed by biochemistry and histopathology. Results The transfusion volume to obtain a MAP of 60 mmHg was lower in animals receiving cryopreserved platelets (5.4 [4.1‐7.1] mL/kg) compared to those receiving liquid stored platelets (7.5 [6.4‐8.5] mL/kg, p < 0.05). ROTEM® clotting times were shorter (45 [41‐48] vs. 49 [45‐53]sec, p < 0.05), while maximum clot firmness was slightly lower (68 [67‐68] vs. 69 [69‐71]mm, p < 0.01). Organ failure was similar in both groups. Conclusions Use of cryopreserved platelets required less transfusion volume to reach a targeted MAP compared to liquid stored platelets, while organ injury was similar. These results provide a rationale for clinical trials with cryopreserved platelets in (traumatic) bleeding.

show abstract

Section: Discussionmentioning

confidence: 99%

The use of cryopreserved platelets in a trauma‐induced hemorrhage model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Otherwise, Thrombosomes ® (Cellphire), which are lyophilized platelet fragments, are under clinical evaluation and might serve as a viable option together with cryopreserved platelets. [18][19][20][21][22][23] The presented case illustrates that even a Norwegian level 1 trauma center with the second-largest integrated blood center in Norway, can be forced to trigger the mass casualty preparedness plan due to one single trauma patient. Transfusion of about 200 units of blood products in a short period of time is challenging when it comes to administration, and to keep record of the ratio between red cells, plasma, and platelets.…”

Section: Discussionmentioning

confidence: 98%

“…Cold storage of platelet concentrates might allow storage with preserved hemostatic function for 14–21 days. Otherwise, Thrombosomes® (Cellphire), which are lyophilized platelet fragments, are under clinical evaluation and might serve as a viable option together with cryopreserved platelets …”

Section: Discussionmentioning

confidence: 99%

How do I get an emergency civilian walking blood bank running?

et al. 2019

View full text Add to dashboard Cite

The shift toward using a transfusion strategy in a ratio to mimic whole blood (WB) functionality has revitalized WB as a viable option to replace severe blood loss in civilian health care. A military‐civilian collaboration has contributed to the reintroduction of WB at Haukeland University Hospital in Bergen, Norway. WB has logistical and hemostatic advantages in both the pre‐ and in‐hospital settings where the goal is a perfectly timed balanced transfusion strategy. In this paper, we describe an event leading to activation of our emergency WB collection strategy for the first time. We evaluate the feasibility of our civilian walking blood bank (WBB) to cover the need of a massive amount of blood in an emergency situation. The challenges are discussed in relation to the different stages of the event with the recommendations for improvement in practice. We conclude that the use of pre‐screened donors as a WBB in a civilian setting is feasible. The WBB can provide platelet containing blood components for balanced blood resuscitation in a clinically relevant time frame.

show abstract

“…After in vitro assays determination of CRY BC-PLT viability up to 9 https://doi.org/10.1016/j.transci.2019.10.008 T months after storage, CRY BC-PLT concentrates for in vivo use were prepared and handled with the same method adopted for the in vitro study [11]. A patented cryopreservation kit has been adopted to avoid one step of external manipulation of the BC-PLTs for cryopreservation.…”

Section: Methodsmentioning

confidence: 99%

“…Only one study has been performed in haematological patients: autologous CRY-PLTs [9] treated with Throm-boSol have been infused to control severe thrombocytopenia secondary to chemotherapy. From this premise, after the development and in vitro validation of a new kit for buffy coat derived platelet cryopreservation (CRY BC-PLT) with DMSO [11], we have evaluated in the pilot in vivo trial NCT02032134. the efficacy and safety of CRY BC-PLTs infused in haematological cancer patients with severe thrombocytopenia…”

Section: Introductionmentioning

confidence: 99%

Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia

Napolitano

Mancuso

Raso

et al. 2019

Transfusion and Apheresis Science

Self Cite

View full text Add to dashboard Cite

The administration of cryopreserved platelets (PLTs) may overcome the limits of platelet shortage and availability, especially during some seasons or in specific contexts like rural areas. After in vitro validation studies, ad hoc prepared buffy coat-derived pooled platelet concentrates (BC-PLTs), treated with dimethyl sulphoxide (DMSO) and cryopreserved (CRY BC-PLTs) at-80°C with a modified Valeri method, were transfused in patients with severe thrombocytopenia secondary to chemotherapy for acute leukaemia (AL). Five inpatients were enrolled in the pivotal clinical trial NCT02032134: 4 males and 1 female with a mean age of 71 years (range: 65-80). Four patients were diagnosed with acute myeloid leukaemia and 1 had acute lymphoblastic leukaemia.Transfusion of one Unit of CRY BC-PLTs resulted effective in active bleeding control in two patients without any adverse reaction or concomitant antihaemorrhagic therapies. CRY BC-PLTs met the currently accepted criteria for cryopreserved PLTs, their transfusion in patients with AL was safe. (Clinical trial: NCT02032134).

show abstract

Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies

Cited by 6 publications

References 24 publications

The use of cryopreserved platelets in a trauma‐induced hemorrhage model

The use of cryopreserved platelets in a trauma‐induced hemorrhage model

How do I get an emergency civilian walking blood bank running?

Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia

Contact Info

Product

Resources

About